Philharmonie, Haarlem | The Netherlands
Psychedelic Science, Ethics, & Business
How we go from psychedelic trails to treatment - from the lab to patient
On September 21, 2022, the OPEN Foundation hosted the "Psychedelic Science, Ethics & Business" event. Serving as a lead-in to the main ICPR conference, this full-day gathering brought together leading figures in the field of psychedelics for a series of in-depth discussions and presentations.
The Psychedelic Science, Ethics & Business day was packed with insights from world-class speakers, including David Nichols from Heffter, Ronan Levy of Field Trip, David Nutt from Imperial College, and Shayla Love of VICE. The event attracted 300 attendees, comprising a mix of entrepreneurs, investors, executives, researchers, and clinicians.
The focus was on a critical and in-depth discussion about the intersection of psychedelic research, treatments, and investment. Topics covered included the burgeoning economy around psychedelics and its impact on science and therapy. Experts from various sectors - businesses, academia, non-profits, and investment companies - shared their perspectives.
Key discussions revolved around bridging the gap between laboratory research and patient care, aligning investments and startup proliferation with core values for public benefit, and examining different business models in psychedelics. These conversations were aimed at understanding how psychedelic science translates into practice, with an emphasis on optimal patient care, accessibility, and equitable treatments.
The event provided unique insights and networking opportunities for all attendees, ensuring they left with a deeper understanding of the rapidly evolving psychedelic ecosystem.
Following the success of the Psychedelic Science, Ethics & Business event (PSBE), and in line with the evolving direction of psychedelic research, this year OPEN Foundation is excited to delve deeper into the critical topic of access.
Recognising the growing interest in psychedelic therapies for mental disorders and the uncertainties surrounding their approval in Europe, the Pathways to Access Summit (Paths) emerges as a pivotal full-day event. Here, we will thoroughly explore the steps involved in registering and integrating psychedelic medicines into European mainstream mental health services. This interactive summit will cover the evolving access pathways, focusing on ensuring safe, timely, and ethical implementation. We'll dissect the complexities of European regulatory frameworks, examining every stage from clinical research to the point of reimbursable treatments, and discuss the roles of various stakeholders at each phase.
Join us to navigate efficiently through this transformative journey in psychedelic medicine.